• The term T-cell is a clipping of “thymus cell,” as these lymphocytes mature in the thymus gland.
• Leukemia was coined in 1848 by Rudolf Virchow from the Greek words leukos (white) and haima (blood), literally meaning “white blood.”
• Lymphoma is derived from the Latin lympha (“water”) and the Greek suffix -oma (“tumor”), first used in the 1870s to describe tumors originating in the lymphatic system.

• Adult T-cell Leukemia/Lymphoma is often abbreviated as ATLL or ATL.
• Historically, the causative virus, HTLV-1, was also called adult T-cell leukemia virus (ATLV).
• The broader category of T-cell malignancies falls under Non-Hodgkin Lymphoma (NHL).
• Specific morphologies of the malignant cells have led to descriptive names like “flower cells” due to their characteristic lobulated nuclei.

• The history of lymphoma began with Thomas Hodgkin’s description in 1832 of what would be named Hodgkin’s disease. All other lymphomas were subsequently grouped as “non-Hodgkin lymphomas”.
• In the 19th century, Rudolf Virchow recognized leukemia as a disease of white blood cells.
• The modern understanding of T-cell lymphomas accelerated significantly in the latter half of the 20th century.
• In 1977, Dr. Kiyoshi Takatsuki and his colleagues in Japan first described Adult T-cell Leukemia (ATL) as a distinct clinical entity, noting its geographic clustering in southwestern Japan.
• A pivotal moment came in 1979-1980 when Dr. Robert Gallo’s laboratory isolated the first human retrovirus, Human T-cell Lymphotropic Virus (HTLV-1), from a patient with cutaneous T-cell lymphoma, and it was subsequently confirmed to be the causative agent of ATL.
• This discovery, which relied on the prior finding of Interleukin-2 to culture T-cells, established a clear viral cause for a human cancer and laid the groundwork for the later discovery of HIV.
• The classification of lymphomas has evolved from purely morphological descriptions to complex systems incorporating immunophenotyping and genetics, with major contributions from figures like Karl Lennert (Kiel classification).

• The discovery of ATL was linked to a distinct geographic clustering in southwestern Japan, suggesting an endemic infectious agent.
• This led to worldwide epidemiological studies that identified other endemic areas, such as the Caribbean, parts of Africa, and South America.
• This geographic distribution is influenced by population migrations.
• Transmission routes—mother-to-child, sexual contact, and blood transfusions—have significant public health implications, leading to the implementation of blood donor screening for HTLV-1 in countries like Japan and the United States.
• Despite being the first human retrovirus discovered, HTLV has been overshadowed by HIV/AIDS, which emerged shortly after, leading some to call HTLV one of the “forgotten viruses”.

• Thomas Hodgkin (1798-1866): First described lymphoma in 1832.
• Rudolf Virchow (1821-1902): Coined the term “leukemia” and was a pioneer in cellular pathology.
• Karl Lennert (1921-2012): A German pathologist who was instrumental in developing the Kiel classification of lymphomas, a foundational system based on immunology.
• Kiyoshi Takatsuki (1930-2021): Led the team that first identified Adult T-cell Leukemia (ATL) as a unique disease entity in Japan in 1977.
• Robert C. Gallo (b. 1937): Co-discovered HTLV-1, the first human retrovirus and the cause of ATL. His lab’s development of methods to grow T-cells in culture (using IL-2) was a critical breakthrough.

• Regarding the discovery of HTLV-1, Dr. Robert Gallo stated, “Emotionally, the most important thing I got satisfaction from was the discovery of the first human retrovirus, the leukemia virus HTLV-1, because it was one of the first viruses shown to be the cause of cancer.”
• A key lesson from the study of lymphomas has been recognizing the price of cure, leading to efforts “to maintain or improve cure rates with fewer complications.”
• From a pathology perspective, the complex history of classification reflects the transition from an “‘eyes-only’ morphological basis… to the more sophisticated tools of immunology and genetics.”

• 1 CD20+, PAX5+, CD3−, high Ki-67
• 2 Pan-cytokeratin+, EMA+, vimentin−
• 3 CD3+, CD2+, CD5+, CD7 variably+, CD20−, TCR-γ/β clonal rearrangement
• 4 CD31+, ERG+, factor VIII-related antigen+

• 1 Sheet-like interstitial infiltration and encasement of structures with relative preservation of myocardial architecture and minimal necrosis
• 2 Hemorrhagic, necrotic mass with sunburst vascular channels originating from right atrium
• 3 Fat-containing, well-circumscribed encapsulated lesion
• 4 Calcified fibroelastic mass attached by a stalk to the fossa ovalis

• 1 Immediate surgical LV wedge resection of the mass
• 2 Empiric CHOP chemotherapy without tissue due to urgency
• 3 Endomyocardial biopsy via LV approach under fluoroscopy alone
• 4 Target the most accessible extracardiac site (e.g., pleural/peritoneal fluid cytology with flow cytometry; if nondiagnostic, PET-CT–guided nodal/soft-tissue core) before cardiac biopsy

• 1 R-CHOP with rituximab due to cardiac involvement
• 2 CHOP-based cytotoxic therapy (no rituximab) with careful preload/afterload management; consider early PET response to adapt therapy
• 3 Imatinib monotherapy given potential KIT mutations
• 4 High-dose methotrexate monotherapy as cardio-selective regimen

• 1 Homogeneous soft-tissue mass that infiltrates and encases coronary/valvular structures with little hemorrhage or calcification
• 2 Predilection for right atrial free wall with extensive intratumoral hemorrhage and necrosis
• 3 Macroscopic fat interdigitating with myocardium
• 4 Dense peripheral calcification with pedunculated attachment

• 1 T1 hyperintense from methemoglobin; T2 hypointense; no diffusion restriction; peripheral nodular enhancement
• 2 T1 and T2 both markedly hypointense; no enhancement; no perfusion
• 3 T1 fat-saturated signal drop consistent with macroscopic fat; minimal enhancement
• 4 T1 iso- to mildly hypointense; T2 hyperintense; avid early enhancement with dynamic perfusion and restricted diffusion (low ADC)

• 1 To replace tissue diagnosis when cardiac masses are present
• 2 Whole-body staging to identify the safest biopsy target and to assess treatment response with Deauville-type metrics
• 3 Differentiating thrombus from tumor based on lack of cardiac motion artifact
• 4 Detecting calcification to discriminate tumor types

Why others are incorrect:
A. The t(14;18) translocation is the hallmark of Follicular Lymphoma, a B-cell malignancy, leading to overexpression of the anti-apoptotic protein BCL2.
B. Constitutive activation of BTK signaling is characteristic of several B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma.
D. While TP53 mutations can occur in many cancers, including some T-cell lymphomas, they are not the primary defining pathogenetic event for ATLL, which is defined by its viral etiology.

Why others are incorrect:
A. CD19, CD20, and CD79a are pan-B-cell markers, used to identify malignancies of B-cell origin.
B. CD13, CD33, and Myeloperoxidase are markers characteristic of the myeloid lineage, used to diagnose acute myeloid leukemia (AML).
D. CD34, TdT, and CD1a are markers of immaturity, typically expressed by precursor T-lymphoblasts in T-lymphoblastic leukemia/lymphoma, not mature T-cell neoplasms.

Why others are incorrect:
A. While paraneoplastic syndromes can cause autonomic dysfunction, direct infiltration is the more common and direct cause of arrhythmia in cardiac lymphoma.
C. Chemotherapy-induced cardiotoxicity is a known complication of treatment (e.g., from anthracyclines), but in this case, the palpitations are a presenting symptom *before* treatment would typically have been initiated.
D. Hyperviscosity syndrome is rare in T-cell lymphomas and is more commonly associated with plasma cell or B-cell lymphoproliferative disorders that produce large amounts of monoclonal protein. It typically causes sludging in small vessels, leading to neurologic or ischemic symptoms rather than primary arrhythmias.

Why others are incorrect:
A. Serum free light chains are primarily used as a tumor marker for plasma cell disorders like multiple myeloma.
B. Beta-2 microglobulin is a prognostic marker in multiple myeloma and some lymphomas, but it is not a component of the standard IPI score.
D. Soluble IL-2 receptor (sIL-2R) is often elevated in T-cell malignancies and reflects T-cell activation and tumor burden, and it is a known prognostic factor in ATLL, but it is not part of the IPI.

Why others are incorrect:
A. While contrast-enhanced CT is a core component of staging, PET/CT is the recommended complete study due to its higher sensitivity for occult disease. CT alone is the standard for non-FDG-avid lymphomas.
C. Whole-body MRI can be used for staging, particularly in pediatric or pregnant patients to avoid radiation, but PET/CT is generally preferred for FDG-avid lymphomas.
D. Gallium-67 scintigraphy was historically used for lymphoma staging but has been almost entirely replaced by the superior spatial resolution and sensitivity of FDG PET/CT.

Why others are incorrect:
A. TTE is an excellent and widely available initial tool for detecting cardiac masses, pericardial effusions, and assessing cardiac function, but it has limited ability to characterize the tissue composition of a mass.
B. CTA provides excellent anatomic detail of the heart and surrounding structures but offers less information about tissue characteristics compared to CMR and involves ionizing radiation.
D. SPECT imaging is primarily used for assessing myocardial perfusion and viability and has a limited role in the primary characterization of cardiac masses.

Why others are incorrect:
A. While any chamber can be involved, the left ventricle is a less common site than the right atrium. Valvular vegetations are characteristic of endocarditis, not lymphoma.
C. The interventricular septum can be involved, but it is not the most common primary site. Calcification is rare in lymphoma and more suggestive of old thrombus or certain other tumor types.
D. Aortic root involvement is uncommon. Pseudoaneurysm is typically a result of infection or trauma, not lymphomatous infiltration.